Towards a better characterization of cirrhosis-associated cardiomyopathy?  by Zaky, Ahmed et al.
Letters to the Editor
192Towards a better characterization of
cirrhosis-associated cardiomyopathy?Table 1. Working deﬁnition of cirrhotic cardiomyopathy [2]. Cardiac dysfunc-
tion in patients suffering from cirrhosis characterized by impaired contractile
responsiveness to stress and/or altered diastolic relaxation with associated
electrophysiological abnormalities in the absence of other known cardiac disease.
Diagnostic criteria:
Systolic dysfunction • Blunted increase in cardiac output 
with exercise, volume challenge or 
pharmacological stimuli
• Resting EF <55%
Diastolic dysfunction • E/A <1
• Prolonged deceleration time 
(>200 msec)
• Prolonged isovolumetric relaxation 
time (<80 msec)
Supportive criteria • Electrophysiological abnormalities
• Chronotropic incompetence
• Electromechanical uncoupling
• Prolonged QTc interval
• Enlarged left atrium
• Increased myocardial mass
• Increased BNP, pro-BNP
• Increased Troponin ITo the Editor:
‘Cirrhotic cardiomyopathy’ arose as a separate clinical entity
when characterized by Lee and colleagues in 1989 [1]. According
to the World Congress of Gastroenterology [2], cirrhotic cardio-
myopathy describes ‘cardiac dysfunction in patients with cirrhosis
characterized by impaired contractile responsiveness to stress, dia-
stolic dysfunction and electrophysiological abnormalities in the
absence of known cardiac disease’ (Table 1). It is known that
patients with cirrhotic cardiomyopathy have high mortality and
morbidity [3]. Thus, there is a need that this entity be more accu-
rately described.
Impaired contractile responsiveness to stress originated from
reports of failure to increase one or more measures of cardiac
performance including: cardiac output, ejection fraction, and
stroke volume in response to stress, with elevation of left ventric-
ular ﬁlling pressures. The changes in cardiac afterload have been
reported inconsistently among studies; with afterload being ele-
vated in some [4,5] and reduced in others [6]. Based on these
observations, the consistent response of left ventricular output
and ﬁlling pressures to varying stress-related changes in after-
load was coined as stress-related contractile dysfunction. As a
consequence, normal ventricular ﬁlling pressures coupled with
an elevated output during resting conditions were perceived as
appropriate function. In other words, left ventricular stroke vol-
ume, cardiac output, and ejection fraction have all been regarded
as presumptive surrogates of intrinsic contractile function as a
function of ﬁlling pressures. Several physiological considerations
would argue against such interpretation of cardiac output and
ejection fraction. First, cardiac output is the product of stroke vol-
ume and heart rate. Therefore, a hyperdynamic state character-
ized by an elevated heart rate may mask an intrinsic contractile
dysfunction. Second, cardiac output and stroke volume are
load-dependent indices that showmutually inverse proportional-
ity with venous return and afterload. Therefore, reduction in
afterload may mask both an intrinsic contractile dysfunction, as
well as mild hypovolemia, during resting conditions. On the other
hand, marked hypovolemia secondary to dehydration may mask
an increase in cardiac output resulting from afterload reduction,
as occurs in exercise. The same limitations apply to ejection frac-
tion as a surrogate of ventricular contractility. An elevated resting
left ventricular end diastolic volume, coupled with a decrease in
end systolic volume due to a reduction in afterload, might explain
the increase in resting ejection fraction that is unrelated to intrin-
sic contractile dysfunction [7]. Third, ejection fraction is a marker
of the more circularly arranged myocardial ﬁbers, which are less
vulnerable than the longitudinally arranged subendocardial
ﬁbers to ischemia and ﬁbrosis [7]. Therefore, a normal resting
ejection fraction may not necessarily represent normal intrinsic
ventricular contractile function. Fourth, there are multiple tech-
nical limitations in the measurement of ejection fraction by echo-
cardiography such as: less accurate border detection in
postoperative and mechanically ventilated patients, and underes-
timation of end diastolic volumes [8]. Fifth, elevated ventricularJournal of Hepatology 2
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highlighting the widely adopted term ‘heart failure with pre-
served ejection fraction’. Consistent with these insights, a recent
study using Doppler tissue imaging in patients with liver cirrho-
sis demonstrated a decline in the resting peak left ventricular sys-
tolic velocity and strain rate, suggesting a decline in the more
vulnerable longitudinally arranged ﬁbers [9]. Taken together,
these observations suggest that more sensitive markers of left
ventricular intrinsic contractile dysfunction could be useful to
better deﬁne cirrhotic cardiomyopathy.
Cardiac diastolic dysfunction has been sought in the current
deﬁnition of cirrhotic cardiomyopathy (Table 1). Normally, the
velocity of early rapid ventricular ﬁlling (denoted by E) is greater
than the later ﬁlling phase that is dependent on atrial contraction
(denoted by A) [10]. Therefore, E/A <1 may denote impaired ven-
tricular relaxation. A low E/A, however, is highly preload-deter-
mined. Decompensated patients suffering from cirrhosis may
retain ﬂuids that may mask an underlying diastolic dysfunction.
Also, E/A <1 may be a normal age-related ﬁnding. Moreover,
The American Society of Echocardiography has included tissue
Doppler imaging criteria in the diagnosis of diastolic dysfunction
[10]. Doppler tissue imaging measures the slow velocity high
amplitude annular tissue motion (denoted by E0) that is less
affected by preload. An increase in the E/E0 ratio has been
used as a more sensitive measure of diastolic dysfunction. It is
therefore necessary to include more sensitive markers of left ven-
tricular diastolic dysfunction into a description of cirrhotic
cardiomyopathy.
Given the emerging evidence of the presence of more sensi-
tive markers of left ventricular dysfunction that are not patho-013 vol. 59 j 190–199
-ND license.
gnomonic to liver cirrhosis, the term ‘cirrhosis-associated’ may
be a more adequate term than ‘cirrhotic’ cardiomyopathy.
In summary, cardiac dysfunction in cirrhosis may not only be
stress-related. There is a need to apply new technology in
exploring more sensitive markers of left ventricular dysfunction
in cirrhosis. Equally important, there is a need to explore the
role of other chambers of the heart, such as the right ventricle,
in the characterization and prognosis of cirrhosis-associated
cardiomyopathy.
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Vitamin D status does not predict sustained virologic response or
ﬁbrosis stage in chronic hepatitis C genotype 1 infection
To the Editor:
In their recent study published in the Journal of Hepatology,
Kitson et al. report that vitamin D status does not predict sus-
tained virologic response (SVR) in genotype 1 chronic hepatitis
C patients [1]. Their ﬁndings are consistent with those of another
group [2], but in contrast to the ﬁndings of several other studies,
in which a correlation between the serum 25-hydroxyvitamin D
[25(OH)D] level and rate of attaining an SVR was identiﬁed
[3–7]. Kitson et al. argue for the strength of their conclusion
and suggest that the correlation between 25(OH)D level and
SVR identiﬁed in the other studies was secondary to confounding
effects. They thereby imply that the 25(OH)D level is not a
determinant of treatment outcome. However, they do not address
the signiﬁcant evidence, from clinical, genetic, animal, and cell
culture studies, that supports a role for endogenous vitamin D
in the treatment response [8]. In light of this evidence, it would
have been prudent for Kitson et al. to have explored the possibil-
ity that certain aspects of their study may have obscured
evidence of a functional relationship between 25(OH)D level
and response to treatment.
For example, whereas all of the study populations, in which a
correlation between 25(OH)D level and the rate of SVR was iden-
tiﬁed, were racially homogeneous, the patients in the Kitson et al.
study were racially diverse. This is of potential consequence in
that there is increasing evidence that there are clinically signiﬁ-
cant racial differences in vitamin D physiology and some of these
may affect genotype 1 chronic hepatitis C treatment outcome
(discussed in [7]). In this regard, it is notable that the Asian
patients in the Kitson et al. study had lower levels of 25(OH)D,
but a higher rate of SVR than the study group as a whole – it is
possible that the level of 25(OH)D necessary for an optimal treat-
ment response is lower in Asians when compared to levels
required for an optimal treatment response in other groups. This
would have attenuated a correlation between 25(OH)D levels and
rate of SVR when their entire group of patients was analyzed
together.
Indeed, there is tangible evidence that there are quantitative
differences in the relationship between 25(OH)D and the
response to genotype 1 chronic hepatitis C treatment outcome
between individual patients. There are alleles of single nucleotide
polymorphisms (SNPs) in two different genes in the vitamin D
metabolic pathway that increase the physiologic effects of
25(OH)D and these same alleles are also associated with an
improved rate of SVR [2,6,9]. This suggests that there is a func-
tional relationship between 25(OH)D level and treatment
response in genotype 1 chronic hepatitis C patients. However,
because the alleles of these SNPs vary between individual
patients, this relationship would be quantitatively different from
patient to patient, such that a correlation may not be evident
when the relationship between 25(OH)D level and SVR is evalu-
ated among a group of patients.
Another characteristic of their study that could have weak-
ened a correlation between 25(OH)D level and treatment
response is the liquid chromatography–tandem mass spectrome-
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